Cutia Therapeutics
HKEX:2487

Watchlist Manager

Cutia Therapeutics

HKEX:2487

Watchlist

Dividends

Price: 8.8 HKD 2.92% Market Closed

Market Cap: 2.8B HKD

Have any thoughts about
Cutia Therapeutics?

Write Note

Write Note Create Alert Ask AI

Add Note Why Create Notes?

Capture your thoughts

Note Buy Sell Hold Pass

US	Johnson & Johnson NYSE:JNJ	Pharmaceuticals
US	Berkshire Hathaway Inc NYSE:BRK.A	Financial Services
US	Bank of America Corp NYSE:BAC	Banking
US	Mastercard Inc NYSE:MA	Technology
US	UnitedHealth Group Inc NYSE:UNH	Health Care
US	Exxon Mobil Corp NYSE:XOM	Energy
US	Pfizer Inc NYSE:PFE	Pharmaceuticals
US	Palantir Technologies Inc NYSE:PLTR	Technology
US	Nike Inc NYSE:NKE	Textiles, Apparel & Luxury Goods
US	Visa Inc NYSE:V	Technology
CN	Alibaba Group Holding Ltd NYSE:BABA	Retail
US	JPMorgan Chase & Co NYSE:JPM	Banking
US	Coca-Cola Co NYSE:KO	Beverages
US	Walmart Inc NYSE:WMT	Retail
US	Verizon Communications Inc NYSE:VZ	Telecommunication
US	Chevron Corp NYSE:CVX	Energy

Add Price Alert

Price Target:

Last Price: 8.8 HKD

We'll email you a reminder when the closing price reaches USD.

If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.

Peter Lynch

Track and Analyze Performance

Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.

Continuous Learning and Adaptation

Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.

Boost Decision Confidence

With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.

Why create notes?

Back

Delete Note

Do you really want to delete this note?
This action cannot be undone.

Remove price alert for reaching

Delete

Cancel

Alert

Cutia Therapeutics

8.8

+0.25 (+2.92%)

52 Week Range	3.77 16.64
Price Target

We'll email you a reminder when the closing price reaches HKD.

Save Alert

Choose the stock you wish to monitor with a price alert.

	Johnson & Johnson NYSE:JNJ	US
	Berkshire Hathaway Inc NYSE:BRK.A	US
	Bank of America Corp NYSE:BAC	US
	Mastercard Inc NYSE:MA	US
	UnitedHealth Group Inc NYSE:UNH	US
	Exxon Mobil Corp NYSE:XOM	US
	Pfizer Inc NYSE:PFE	US
	Palantir Technologies Inc NYSE:PLTR	US
	Nike Inc NYSE:NKE	US
	Visa Inc NYSE:V	US
	Alibaba Group Holding Ltd NYSE:BABA	CN
	JPMorgan Chase & Co NYSE:JPM	US
	Coca-Cola Co NYSE:KO	US
	Walmart Inc NYSE:WMT	US
	Verizon Communications Inc NYSE:VZ	US
	Chevron Corp NYSE:CVX	US

Delete Alert

This alert will be permanently deleted.

Remove note

Delete

Cancel

Ask me anything about

Cutia Therapeutics

What unique competitive advantages
does Cutia Therapeutics hold over its rivals?

What risks and challenges
does Cutia Therapeutics face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Provide an overview of the primary business activities
of Cutia Therapeutics.

What unique competitive advantages
does Cutia Therapeutics hold over its rivals?

What risks and challenges
does Cutia Therapeutics face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Cutia Therapeutics.

Provide P/S
for Cutia Therapeutics.

Provide P/E
for Cutia Therapeutics.

Provide P/OCF
for Cutia Therapeutics.

Provide P/FCFE
for Cutia Therapeutics.

Provide P/B
for Cutia Therapeutics.

Provide EV/S
for Cutia Therapeutics.

Provide EV/GP
for Cutia Therapeutics.

Provide EV/EBITDA
for Cutia Therapeutics.

Provide EV/EBIT
for Cutia Therapeutics.

Provide EV/OCF
for Cutia Therapeutics.

Provide EV/FCFF
for Cutia Therapeutics.

Provide EV/IC
for Cutia Therapeutics.

Show me price targets
for Cutia Therapeutics made by professional analysts.

What are the Revenue projections
for Cutia Therapeutics?

How accurate were the past Revenue estimates
for Cutia Therapeutics?

What are the Net Income projections
for Cutia Therapeutics?

How accurate were the past Net Income estimates
for Cutia Therapeutics?

What are the EPS projections
for Cutia Therapeutics?

How accurate were the past EPS estimates
for Cutia Therapeutics?

What are the EBIT projections
for Cutia Therapeutics?

How accurate were the past EBIT estimates
for Cutia Therapeutics?

Compare the revenue forecasts
for Cutia Therapeutics with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Cutia Therapeutics and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Cutia Therapeutics against its competitors.

Analyze the profit margins
(gross, operating, and net) of Cutia Therapeutics compared to its peers.

Compare the P/E ratios
of Cutia Therapeutics against its peers.

Discuss the investment returns and shareholder value creation
comparing Cutia Therapeutics with its peers.

Analyze the financial leverage
of Cutia Therapeutics compared to its main competitors.

Show all profitability ratios
for Cutia Therapeutics.

Provide ROE
for Cutia Therapeutics.

Provide ROA
for Cutia Therapeutics.

Provide ROIC
for Cutia Therapeutics.

Provide ROCE
for Cutia Therapeutics.

Provide Gross Margin
for Cutia Therapeutics.

Provide Operating Margin
for Cutia Therapeutics.

Provide Net Margin
for Cutia Therapeutics.

Provide FCF Margin
for Cutia Therapeutics.

Show all solvency ratios
for Cutia Therapeutics.

Provide D/E Ratio
for Cutia Therapeutics.

Provide D/A Ratio
for Cutia Therapeutics.

Provide Interest Coverage Ratio
for Cutia Therapeutics.

Provide Altman Z-Score Ratio
for Cutia Therapeutics.

Provide Quick Ratio
for Cutia Therapeutics.

Provide Current Ratio
for Cutia Therapeutics.

Provide Cash Ratio
for Cutia Therapeutics.

What is the historical Revenue growth
over the last 5 years for Cutia Therapeutics?

What is the historical Net Income growth
over the last 5 years for Cutia Therapeutics?

What is the current Free Cash Flow
of Cutia Therapeutics?

Discuss the annual earnings per share (EPS)
trend over the past five years for Cutia Therapeutics.

Section:

Wall Street
Price Targets

Price Targets Summary
Cutia Therapeutics

Wall Street analysts forecast Cutia Therapeutics stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Cutia Therapeutics is 11.05 HKD with a low forecast of 8.08 HKD and a high forecast of 15.96 HKD.

Lowest

Price Target

8.08 HKD

8% Downside

Average

Price Target

11.05 HKD

26% Upside

Highest

Price Target

15.96 HKD

81% Upside

Cutia Therapeutics Competitors:
Price Targets

VNDA

Vanda Pharmaceuticals Inc

159% Upside

ORKA

Oruka Therapeutics Inc

189% Upside

PHM

Pharma Mar SA

17% Upside

VTGN

VistaGen Therapeutics Inc

437% Upside

VNDA

Vanda Pharmaceuticals Inc

159% Upside

ORKA

Oruka Therapeutics Inc

189% Upside

PHM

Pharma Mar SA

17% Upside

VTGN

VistaGen Therapeutics Inc

437% Upside

688520

Sinocelltech Group Ltd

25% Downside

HUMA

Humacyte Inc

279% Upside

NTLA

Intellia Therapeutics Inc

237% Upside

4974

Takara Bio Inc

56% Upside

Revenue
Forecast

Revenue Estimate
Cutia Therapeutics

For the last 2 years the compound annual growth rate for Cutia Therapeutics's revenue is 396%. The projected CAGR for the next 3 years is 70%.

396%

Past Growth

70%

Estimated Growth

N/A

Estimates Accuracy

N/A

Average

What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Cutia Therapeutics

N/A

Past Growth

N/A

Estimated Growth

N/A

Estimates Accuracy

N/A

Average

What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Cutia Therapeutics

N/A

Past Growth

N/A

Estimated Growth

N/A

Estimates Accuracy

N/A

Average

What are analyst estimates?

What is Cutia Therapeutics's stock price target?

Price Target
11.05 HKD

According to Wall Street analysts, the average 1-year price target for Cutia Therapeutics is 11.05 HKD with a low forecast of 8.08 HKD and a high forecast of 15.96 HKD.

What is Cutia Therapeutics's Revenue forecast?

Projected CAGR
70%

For the last 2 years the compound annual growth rate for Cutia Therapeutics's revenue is 396%. The projected CAGR for the next 3 years is 70%.

	Franklin Covey Co NYSE:FC	20.82 USD -2.85%
	Mohawk Industries Inc NYSE:MHK	115.04 USD 2.42%
	Ardmore Shipping Corp NYSE:ASC	10.26 USD 3.01%
	ASGN Inc NYSE:ASGN	51.315 USD -0.05%
	Skyworks Solutions Inc NASDAQ:SWKS	77.68 USD 0.06%
	Weatherford International PLC NASDAQ:WFRD	57.37 USD 1.68%

	Johnson & Johnson NYSE:JNJ	158.12 USD 1.18%
	Bank of America Corp NYSE:BAC	47.145 USD 0.65%
	Mastercard Inc NYSE:MA	562.84 USD -0.4%
	Salesforce Inc NYSE:CRM	266.14 USD -1.76%
	Abbvie Inc NYSE:ABBV	194.105 USD 1.83%
	Home Depot Inc NYSE:HD	375.738 USD 1.27%

	Monolithic Power Systems Inc NASDAQ:MPWR	742.946 USD -1.09%
	NVIDIA Corp NASDAQ:NVDA	162.55 USD -0.2%
	Pro Medicus Ltd ASX:PME	317.69 AUD 0.96%
P	Plover Bay Technologies Ltd HKEX:1523	6.11 HKD -1.61%
S	SciClone Pharmaceuticals (Holdings) Ltd HKEX:6600	18.72 HKD
	Alfa Financial Software Holdings PLC LSE:ALFA	219 GBX -0.45%

	Salesforce Inc NYSE:CRM	266.14 USD -1.76%
	Accenture PLC NYSE:ACN	288.325 USD -3.05%
	ServiceNow Inc NYSE:NOW	974.195 USD -3.9%
	Spotify Technology SA NYSE:SPOT	707.56 USD -2.02%
	EOG Resources Inc NYSE:EOG	121.57 USD -0.26%
	Monster Beverage Corp NASDAQ:MNST	59.36 USD -0.35%

Cutia Therapeutics
HKEX:2487